Logo

NUS

Nu Skin Enterprises, Inc.

NUS

Nu Skin Enterprises, Inc. • NYSE
$9.89 ▼ -4.44% (-0.46)
Market Cap $490.33 M
52w High $14.62
52w Low $5.32
Dividend Yield 0.24%
P/E 4.52
Volume 295.14K
Outstanding Shares 49.58M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $364.211M ▼ $235.081M ▲ $17.079M ▼ 4.689% ▼ $0.35 ▼ $32.23M ▼
Q2-2025 $386.138M ▲ $234.953M ▼ $21.119M ▼ 5.469% ▼ $0.43 ▼ $42.989M ▼
Q1-2025 $364.49M ▼ $256.864M ▼ $107.515M ▲ 29.497% ▲ $2.16 ▲ $152.09M ▲
Q4-2024 $445.552M ▲ $332.228M ▲ $-36.105M ▼ -8.103% ▼ $-0.73 ▼ $-35.489M ▼
Q3-2024 $430.145M $283.232M $8.302M 1.93% $0.17 $37.119M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $252.997M ▼ $1.424B ▼ $624.611M ▼ $799.795M ▲
Q2-2025 $264.159M ▲ $1.444B ▲ $655.939M ▲ $787.754M ▲
Q1-2025 $213.551M ▲ $1.391B ▼ $637.442M ▼ $753.969M ▲
Q4-2024 $197.994M ▼ $1.469B ▼ $817.459M ▼ $651.455M ▼
Q3-2024 $237.828M $1.583B $876.02M $706.875M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $17.079M ▼ $27.481M ▼ $-9.915M ▼ $-26.876M ▼ $-12.372M ▼ $17.566M ▼
Q2-2025 $21.119M ▼ $35.795M ▲ $8.793M ▼ $9.268M ▲ $60.389M ▲ $35.777M ▲
Q1-2025 $107.515M ▲ $389K ▼ $181.544M ▲ $-166.295M ▼ $16.887M ▲ $-13.195M ▼
Q4-2024 $-36.105M ▼ $25.785M ▼ $-13.622M ▼ $-43.626M ▼ $-40.868M ▼ $13.202M ▼
Q3-2024 $8.302M $31.432M $-6.547M $-28.778M $3.501M $22.836M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Manufacturing Segment
Manufacturing Segment
 $50.00M ▲$60.00M ▲$60.00M ▲$50.00M ▼
Nu Skin
Nu Skin
 $360.00M ▲$310.00M ▼$0 ▼$0 ▲
Rhyz Other Segment
Rhyz Other Segment
 $40.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Nu Skin’s sales have been drifting down over the past few years, and profits have come under clear pressure. While the company used to earn solid profits earlier in the period shown, more recently it has slipped into an operating loss and a net loss. That tells you the business is facing both weaker demand and tighter margins at the same time. In short, the income statement shows a company in transition: shrinking revenue, thinner profitability, and a recent move into the red as it invests and adjusts its model.

Balance Sheet

Balance Sheet The balance sheet is still constructive but has become less robust over time. Total assets have edged down, cash on hand has declined from earlier levels, and shareholders’ equity has gradually shrunk, which means the financial cushion for absorbing shocks is smaller than it used to be. Debt is meaningful but not extreme, and equity remains positive, so the capital structure is not alarming. Still, the trend points to a business that has been using up some of its financial flexibility while results have softened.

Cash Flow

Cash Flow Despite the recent accounting loss, Nu Skin continues to generate positive cash from its core operations, which is a key stabilizing factor. The company has also kept its investment spending on physical assets relatively modest, so free cash flow has stayed positive, though clearly below the standout levels seen a few years ago. Overall, cash flow quality looks better than the income statement alone might suggest, but the direction is negative: the business is throwing off less cash than before, which limits how aggressively it can invest, reduce debt, or return capital without making trade‑offs.

Competitive Edge

Competitive Edge Nu Skin sits in a crowded and fast-moving beauty and wellness market, with the added complexity of a direct-selling and affiliate-based distribution model. Its long history, established brands, and global network of affiliates give it a real presence and customer reach that new entrants would find hard to copy quickly. However, the model depends heavily on keeping affiliates motivated and active, an area where the company has acknowledged pressure. At the same time, it faces intense competition from traditional beauty brands, consumer health companies, and device makers, many of which sell directly online. The company’s emerging edge lies in offering an integrated ecosystem of devices, skincare, and supplements, but it must execute well to turn that into renewed growth and stronger loyalty.

Innovation and R&D

Innovation and R&D Innovation is one of Nu Skin’s clearer bright spots. The company is leaning into connected beauty and wellness devices, app-based personalization, and the use of artificial intelligence in ingredient discovery and product matching. Its ecosystem approach—devices that pair with consumable products and subscription-based supplements—aims to create recurring, high-engagement customer relationships. With a sizeable in-house scientific team and multiple labs, the company is not just marketing-led; it has real product development capabilities. Upcoming launches like the AI-driven Prysm iO platform and expansion into new markets, such as India, show a forward-looking roadmap. The risk is that these innovations must scale commercially and offset declines in the traditional direct-selling model; the opportunity is that, if successful, they could reposition Nu Skin as a tech-enabled wellness platform rather than a conventional multi-level marketer.

Summary

Nu Skin is in the middle of a strategic and financial transition. The recent track record shows falling sales and a move from steady profitability to losses, alongside a gradual erosion of balance sheet strength. At the same time, cash flow remains positive, which helps support ongoing investments and provides some breathing room. Strategically, the company is trying to reinvent itself around connected devices, personalization, and an integrated beauty-and-wellness offering, building on decades of scientific work and brand equity. Its competitive position still benefits from scale, brand recognition, and a global affiliate network, but that network is under strain and the broader market is highly competitive. Going forward, the key questions are whether Nu Skin can stabilize and re-energize its sales engine, successfully commercialize its new technology platforms, and rebuild profitability without overextending its balance sheet. The answers to those questions will matter more than any single year’s results.

NEWS

November 7, 2025 · 8:45 AM UTC

Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q3

Read more

November 6, 2025 · 4:06 PM UTC

Nu Skin Enterprises Reports Third Quarter Earnings

Read more

November 6, 2025 · 4:05 PM UTC

Nu Skin Enterprises Announces Quarterly Dividend

Read more

October 16, 2025 · 4:05 PM UTC

Nu Skin Enterprises to Announce Third Quarter 2025 Financial Results

Read more

September 30, 2025 · 4:05 PM UTC

Nu Skin Ranked the World's #1 Company for Beauty and Wellness Device Systems for Second Consecutive Year

Read more